newsfilter
← Latest News
GlobeNewswire·

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated as development